Eli Lilly’s Alzheimer’s drug faces NHS rejection By Investing.com

Eli Lilly and Company’s new Alzheimer’s drug, donanemab, is expected to be refused approval by the UK’s National Health Service (NHS), the Telegraph reports. According to sources cited by the newspaper, the National Institute for Health and Care Excellence (NICE), which is responsible for approving medicines for use in the NHS, is not expected to approve the treatment.

The National Institute for Health and Care Excellence (NICE) is also unlikely to reverse its previous decision to reject another Alzheimer’s drug, lecanimab, despite it being the first approved treatment in the country that has been proven to slow the progression of the disease. The Medicines and Healthcare Products Regulatory Agency (MHRA) earlier this week cited lecanimab’s high costs and the intensive monitoring required for side effects as reasons for its poor value for taxpayers. .

Donanemab has been recognized by scientists as a more effective treatment in slowing the progression of Alzheimer’s disease, with some calling it the “best ever” treatment for the condition. However, concerns about the risk of side effects could prevent the Medicines and Health Regulatory Authority from approving the drug. Donanemab and lecanimab are both approved for use in the United States.

A decision on the approval of donanemab has been delayed, with initial plans by the regulatory body to make a decision in July, at the same time as approval for its use in the United States. So far, Eli Lilly (NYSE: LLY), NICE, NICE and the NHS have not responded to requests for comment on the report.

Reuters contributed to this article.

This article was translated with the help of artificial intelligence software after review by an editor. For more information, check its terms and conditions